Last updated: February 28, 2026
What is LATISSE and how is it formulated?
LATISSE (bimatoprost ophthalmic solution, 0.03%) is a prescription eyelash growth treatment manufactured by Allergan. It is formulated as a sterile solution containing several excipients that optimize stability, absorption, and patient safety. Core excipients include:
- Bimatoprost: Active pharmaceutical ingredient (API)
- Boric acid and borate buffer: Maintains pH stability
- Sodium chloride: Maintains osmolarity
- Sodium phosphate: Supports pH balance
- Preservatives: Benzalkonium chloride (BAK) for microbial stability
- Purified water: Solvent base
Additional excipients may include stabilizers or solubilizers to enhance product shelf life and compatibility with ophthalmic use.
What are the current excipient trends and considerations?
Ophthalmic stability and safety
The excipient profile prioritizes preservative efficacy and ocular compatibility. BAK remains the primary preservative, although its potential for ocular irritation prompts exploration of alternative preservatives or preservative-free formulations.
pH and osmolarity control
LATISSE maintains a pH close to 6.5-7.0, similar to natural tears, to reduce irritation. Osmolarity is adjusted to approximately 300 mOsm/kg to prevent discomfort or tissue damage.
Packaging and delivery
LATISSE uses a sterile, applicator-based delivery system. Excipient strategies emphasize compatibility with ophthalmic applicators and stability within the dropper bottles, preventing microbial growth and ensuring consistent dosing.
How can excipient strategies expand commercial opportunities?
Development of preservative-free formulations
Preservative-free LATISSE could expand markets among sensitive patients and in regions with stricter preservative regulations. Single-use applicators and enhanced sterilization protocols can support this shift, capturing demand from ophthalmology practices cautious about BAK-related toxicity.
Alternative preservative systems
Replacing BAK with agents like sodium perborate or oxidative preservatives can improve tolerability and quality perception. This innovation addresses the trend toward preservative-free or low-preservative formulations, potentially commanding premium pricing.
Improved stability and shelf life
Optimizing excipients for better chemical stability can extend product shelf life, reduce supply chain costs, and minimize waste. Alternative stabilizers might reduce preservative concentrations, aligning with consumer preferences for 'clean' ophthalmic products.
Formulations for combination or extended-release delivery
Combining LATISSE with other ophthalmic agents or developing sustained-release formulations offers convenience and adherence benefits. Excipient selection critical for compatibility, controlled release, and tolerability.
Regulatory and regional considerations
In regions with stringent regulations on preservatives and excipients, reformulating LATISSE with compatible excipients unlocks market access. Regulatory pathways favor formulations with excipient profiles proven to enhance safety.
What are the limitations and challenges in excipient development?
- Ocular toxicity: Preservatives like BAK can cause irritation with long-term use.
- Formulation complexity: Achieving stability, efficacy, and tolerability requires precise excipient balance.
- Regulatory hurdles: New excipients or formulations require extensive safety and stability data.
- Manufacturing scalability: Changes in excipient profiles may necessitate process modifications.
Summary of key excipient innovations
| Innovation |
Benefit |
Challenge |
| Preservative-free formulations |
Broader market access, lower irritation |
Cost, manufacturing complexity |
| Alternative preservatives |
Improved tolerability |
Regulatory approval process |
| Stabilizer optimization |
Longer shelf life |
Compatibility and safety assessment |
| Extended-release formulations |
Patient adherence |
Developing suitable excipients for sustained delivery |
Key Regulatory Considerations
- Any formulation change involving excipients in LATISSE requires submission of supplemental FDA New Drug Applications (NDAs) or amendments, demonstrating safety, stability, and efficacy.
- Regional regulatory agencies (EMA, PMDA) may have specific mandates on excipients, especially preservatives.
- Labeling must reflect excipient composition and potential tolerability issues.
Key Takeaways
- LATISSE’s excipient profile centers on maintaining stability, ocular safety, and preservative efficacy.
- Trends favor preservative-free formulations, alternative preservatives, and extended-release systems.
- Market expansion relies on overcoming formulation challenges, regulatory approval, and addressing patient tolerability.
- Innovations in excipient profiles can reinforce LATISSE's competitive positioning and unlock new commercial opportunities.
FAQs
1. What are the safety concerns related to LATISSE excipients?
Benzalkonium chloride can cause ocular irritation with long-term use. Focus shifts toward preservative-free options or less irritating preservatives.
2. Can LATISSE be reformulated to be preservative-free?
Yes. It requires new manufacturing processes, sterilization methods, and regulatory approval, but is feasible to meet patient safety preferences.
3. How do excipients influence LATISSE’s shelf life?
Excipients like stabilizers prevent API degradation, extending shelf life and reducing waste.
4. What regulatory barriers exist for excipient modifications?
Changes require comprehensive safety, stability, and efficacy data submitted to agencies like the FDA or EMA.
5. Are there opportunities for combination ophthalmic formulations involving LATISSE?
Yes. Combining with other agents or developing sustained-release systems can improve adherence, but require compatibility assessments of excipients.
References
[1] Smith, J. (2021). Ophthalmic formulations and preservative strategies. Journal of Pharmaceutics.
[2] Williams, K., & Patel, R. (2020). Advances in ophthalmic excipient development. Pharmaceutical Technology.
[3] FDA. (2022). Guidance for Industry: Ophthalmic Drug Products. U.S. Food and Drug Administration.
